Home GPCR & G Protein Glucagon Receptor

Glucagon Receptor Agonists

Cat.No. Product Name Information Product Use Citations Product Validations
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
P1247 Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
E7333 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
S9852 Orforglipron (LY3502970) Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779 DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. This compound attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230 Retatrutide (LY3437943) Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
P1231New Mazdutide (IBI362, LY330567) Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D).
E0021 Apraglutide (FE 203799)

Apraglutide (FE 203799) is a potent and highly selective GLP-2 agonist with EC50s of 0.03 nM and 0.07 nM for hGLP-2 Receptor and rGLP-2 Receptor, respectively.